|
rs1001179
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The results demonstrated that the rs1001179 polymorphism was associated with an increased cancer risk in the recessive and homozygote models (TT vs. CC: OR = 1.19, P = 0.01; TT vs. CT+CC: OR = 1.19, P <0.001).
|
27449288 |
2016 |
|
rs10012
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To derive a more precise estimation of the association between the CYP1B1 polymorphisms and cancer risk, we performed a meta-analysis to investigate the association between cancer susceptibility and CYP1B1 Leu432Val, Asn453Ser, Arg48Gly, and Ala119Ser polymorphisms.
|
25475389 |
2015 |
|
rs10035650
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Cancer risk susceptibility loci in a Swedish population.
|
29299148 |
2017 |
|
rs1005464
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Subjects carrying the AA genotype of rs1005464 had significant decreased cancer risk (age-adjusted OR = 0.44, 95% CI of 0.23-0.85) compared with those carrying the GG genotype.
|
25391427 |
2015 |
|
rs10069690
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The cancer risk alleles of rs2242652 and rs1006</span>9690, respectively, increase silencing and generate a truncated TERT splice variant.
|
23535731 |
2013 |
|
rs10069690
|
|
|
0.020 |
GeneticVariation |
BEFREE |
This meta-analysis suggested that the TERT rs10069690 polymorphism may be a risk factor for cancer, especially breast cancer, ovarian cancer, lung cancer, thyroid cancer, and RCC.
|
31454181 |
2019 |
|
rs10074991
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To sum up, PRKAA1 rs13361707 polymorphism is not participant with the increased risk of cancer, while the A allele of PRKAA1 rs10074991 revealed a significant decrease risk.
|
30340465 |
2018 |
|
rs10109984
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The results showed that no significant associations with cancer risk were found in any model in terms of rs7003908, rs7830743 and rs10109984 when all studies were pooled into the meta-analysis.
|
23108991 |
2013 |
|
rs1012049
|
|
|
0.010 |
GeneticVariation |
BEFREE |
One additional sample showed that four SNPs were associated with risk of cancer (top SNP rs1339197 with p = 4.1 × 10<sup>-3</sup>), 12 SNPs associated with LDL-cholesterol (top SNP rs4544930 with p = 3.47 × 10<sup>-3</sup>), and eight SNPs associated with total cholesterol (top SNP rs1012049 with p = 6.09 × 10<sup>-3</sup>).
|
28987514 |
2018 |
|
rs1012477
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Overall analysis did not suggest a global role of rs1012477 in cancer susceptibility.
|
25837749 |
2015 |
|
rs1012477
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Study distribution by tumor was as follows: breast cancer (n=15), prostate cancer (n=3), pancreatic cancer (n=2), non-Hodgkin's lymphoma (n=2), glioma (n=1), chronic lymphocytic leukemia (n=1), colorectal cancer (n=1), non-small cell lung cancer (n=1) and ovarian cancer (n=1).We identified 10 single nucleotide polymorphisms (SNPs) significantly associated with cancer risk: NPAS2 rs10165970 (mixed and breast cancer shiftworkers), rs895520 (mixed), rs17024869 (breast) and rs7581886 (breast); CLOCK rs3749474 (breast) and rs11943456 (breast); RORA rs7164773 (breast and breast cancer postmenopausal), rs10519097 (breast); RORB rs7867494 (breast cancer postmenopausal), PER3 rs1012477 (breast cancer subgroups) and assessed the level of quality evidence to be intermediate.
|
28177907 |
2017 |
|
rs10131
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found that GA+AA of LIG4 rs10131 was associated with increased risk of glioma in those without family history of cancer, and the OR (95% CI) was 1.78 (1.12-2.83).
|
25973104 |
2015 |
|
rs10132552
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Certain polymorphisms within MEG3 are implicated in cancer risk (rs7158663, rs4081134 and rs11160608) or therapeutic response of cancer patients (rs10132552).
|
31326791 |
2019 |
|
rs10138053
|
|
C |
0.700 |
GeneticVariation |
GWASCAT |
Cancer risk susceptibility loci in a Swedish population.
|
29299148 |
2017 |
|
rs1015213
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To investigate if the single nucleotide polymorphisms rs3753841, rs1015213 and rs11024102, recently implicated in the development of acute primary angle closure or primary angle closure glaucoma, are associated with ocular biometric characteristics of British adults in the European Prospective Investigation of Cancer-Norfolk eye study.
|
23505305 |
2013 |
|
rs10160246
|
|
A |
0.700 |
GeneticVariation |
GWASCAT |
Cancer risk susceptibility loci in a Swedish population.
|
29299148 |
2017 |
|
rs1016343
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The results also suggested that other SNPs were correlated with overall cancer risk, namely, two in HOTAIR (HOX transcript antisense RNA: rs920778C/T and rs7958904 G/C) and two in PRNCR1 (rs1016343C/T and rs16901946 A/G).
|
28342449 |
2017 |
|
rs1016343
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Our meta-analysis results revealed that these four lncRNAs polymorphisms (HOTAIR rs920778, PRNCR1 rs1016343 and rs16901946, POLR2E rs3787016) can contribute to cancer risk.
|
28159929 |
2017 |
|
rs1016343
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Moreover, four prostate cancer-associated ncRNA 1 (PRNCR1, rs16901946 G/A, rs13252298 G/A, rs1016343 T/C, and rs1456315 G/A) SNPs were in association with cancer risk.
|
29802154 |
2018 |
|
rs10165970
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Study distribution by tumor was as follows: breast cancer (n=15), prostate cancer (n=3), pancreatic cancer (n=2), non-Hodgkin's lymphoma (n=2), glioma (n=1), chronic lymphocytic leukemia (n=1), colorectal cancer (n=1), non-small cell lung cancer (n=1) and ovarian cancer (n=1).We identified 10 single nucleotide polymorphisms (SNPs) significantly associated with cancer risk: NPAS2 rs10165970 (mixed and breast cancer shiftworkers), rs895520 (mixed), rs17024869 (breast) and rs7581886 (breast); CLOCK rs3749474 (breast) and rs11943456 (breast); RORA rs7164773 (breast and breast cancer postmenopausal), rs10519097 (breast); RORB rs7867494 (breast cancer postmenopausal), PER3 rs1012477 (breast cancer subgroups) and assessed the level of quality evidence to be intermediate.
|
28177907 |
2017 |
|
rs10175368
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Interestingly when classified by lifestyle factors, no associations of genotypes were found for non-smokers and non-drinkers, whereas on the contrary, minor type at rs2567206 and rs10175368 increased and major G-C-T-G decreased risk for cancer among smokers and drinkers.
|
30133114 |
2018 |
|
rs1018379423
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our data show that weak activation of the Mek/Erk pathway underpins RASopathies, but in cancer, (L597V)Braf epistatically modifies the transforming effects of driver oncogenes.
|
22892241 |
2012 |
|
rs1019340046
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our results show: (1) wild-type p53 stimulates the transcription of reporter genes with p53CON and RGC in their 5' region while most p53 mutants occurring in human cancers have lost this activity; (2) the R273H mutant retains transcriptional activity for the p53CON sequence but not RGC; (3) some mutants are temperature-sensitive for the transcriptional activity with the p53CON but not the RGC sequence; (4) p53 mutants vary in their ability to inhibit wild-type p53 transactivation but there is no difference between p53CON and RGC sequences; (5) lung cancer cells with endogenous mutant p53 proteins (M246I in H23 cells and R248L in H322 cells) retain transcriptional activity for the p53CON but not the RGC sequence.
|
8336941 |
1993 |
|
rs10203853
|
|
|
0.010 |
GeneticVariation |
BEFREE |
UGT1A haplotype analysis found that the T-G haplotype in UGT1A10 exon 1 (block 2: rs17864678, rs10929251) decreased cancer risk for the colon [proximal (OR = 0.28, 95% CI = 0.11–0.69) and for the distal colon (OR = 0.32, 95% CI = 0.12–0.91)], and that the C-T-G haplotype in the 3′ region flanking the UGT1A shared exons (block 11: rs7578153, rs10203853, rs6728940) increased CRC risk in males (OR = 2.56, 95% CI = 1.10–5.95).
|
24822274 |
2014 |
|
rs10204525
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The results of meta-analysis: the PDCD-1.5 (rs2227981) and PDCD-1.3 (rs11568821) polymorphisms were associated with decreased risk of cancer (rs2227981: OR = 0.75, 95% CI: 0.64-0.86, P < 0.0001 for TT vs TC + CC; rs11568821: OR = 0.79, 95% CI: 0.65-0.96, P = 0.02 for TC vs TT), while no significant associations were found for the other 3 polymorphisms (PDCD-1.9 [rs2227982] polymorphism: OR = 1.03, 95% CI: 0.90-1.18, P = 0.66 for CC + TC vs TT; PDCD1 rs7421861 polymorphism: OR = 1.10, 95% CI: 0.96-1.25, P = 0.16 for CC + TC vs TT; PDCD-1.6 [rs10204525] polymorphism: OR = 0.93, 95% CI: 0.82-1.05, P = 0.24 for GG + GA vs AA).
|
27749524 |
2016 |